Evidence map›Paper›PMID 35011875›Full record

ArticleJournal of clinical medicine2021

Elevated TAT in COVID-19 Patients with Normal D-Dimer as a Predictor of Severe Respiratory Failure: A Retrospective Analysis of 797 Patients.

Yuichiro Takeshita, Jiro Terada, Yasutaka Hirasawa, Taku Kinoshita, Hiroshi Tajima, Ken Koshikawa, Toru Kinouchi, Yuri Isaka, Yu Shionoya, Atsushi Fujikawa and 3 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuichiro TakeshitaDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.ORCID 0000-0001-7829-8968
Jiro TeradaDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.
Yasutaka HirasawaDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.ORCID 0000-0001-5718-5120
Taku KinoshitaDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.
Hiroshi TajimaDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.
Ken KoshikawaDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.
Toru KinouchiDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.
Yuri IsakaDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.ORCID 0000-0002-8299-4250
Yu ShionoyaDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.ORCID 0000-0001-6706-5595
Atsushi FujikawaDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.
Yuji TadaDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.
Chiaki NakasekoDepartment of Hematology, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.ORCID 0000-0003-1175-226X
Kenji TsushimaDepartment of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita 286-8520, Japan.

Funding

International University of Health and Welfare IUHW research grant 2020
6 · The paper itself

Abstract

Although previous studies have revealed that elevated D-dimer in the early stage of coronavirus 2019 (COVID-19) indicates pulmonary intravascular coagulation, the state of coagulation/fibrinolysis disorder with normal D-dimer is unknown. The study aimed to investigate how coagulation/fibrinolysis markers affect severe respiratory failure in the early stage of COVID-19. Among 1043 patients with COVID-19, 797 patients were included in our single-center retrospective study. These 797 patients were divided into two groups, the normal D-dimer and elevated D-dimer groups and analyzed for each group. A logistic regression model was fitted for age, sex, body mass index (BMI) ≥ 30 kg/m

Indexed as

coagulationCOVID-19D-dimerdisseminated intravascular coagulationfibrinolysisrespiratory failureTAT

Identifiers

PMID35011875
PMCPMC8745035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.